Sasha Jovanovic
4 min read
Illumina just released its Q3 2026 report and the market reacted sharply. The stock fell 18.6% today to about US$236, even though the company posted Basic EPS of US$1.46 and net income from continuing operations of US$220 million for the quarter. Traders focused on the valuation concern following a rich 39.9x trailing P/E. The fundamentals presented a more measured picture. Margins stayed healthy, guidance for full year revenue and earnings moved higher, and free cash flow remained solid. The key question now is whether this selloff reflects fear or an overreaction to a crowded trade.
Love Illumina’s solid margins and free cash flow but worried about paying up for a 39.9x trailing P/E in a crowded trade? You may want to explore our 33 high quality undervalued stocks for ideas that pair comparatively lower valuations with fundamental strength.
Q3 2026 Earnings Summary
-
Revenue (Q3 2026 vs. Q3 2025): US$1,129 million vs. US$1,084 million (up 4.2%)
-
Net Income from Continuing Operations (Q3 2026 vs. Q3 2025): US$220 million vs. US$150 million (up 46.7%)
-
Basic EPS (Q3 2026 vs. Q3 2025): US$1.46 vs. US$0.98 (up 48.6%)
-
Net Profit Margin (Trailing 12 Months vs. Prior Year): 19.7% vs. 16.5% (improved by 3.2 percentage points)
Tired of scrolling through dense earnings releases and raw figures to piece together Illumina’s story? Get a clean visual snapshot of Illumina’s valuation and how the market is pricing its latest results in the interactive company report for Illumina.
Evaluating Illumina’s Bull Case On Clinical And Data Mix
The bullish story hangs on Illumina turning clinical and data heavy offerings into a richer earnings engine over time.
“The main factor that would need to go right is that Illumina continues to convert clinical demand, multiomics products and BioInsight into higher margin consumables and data revenue while managing research softness, China constraints and legal or competitive pressures.”
Q3 shows real traction on that goal. Clinical consumables grew in the mid teens in Rest of World, while research and applied consumables declined mid to high single digits. Sequencing services and other, where Billion Cell Atlas and BioInsight sit, rose faster than the group and helped Illumina lift operating margin to 25%, ahead of prior guidance.
One Narrative disagrees with today’s price. → See where this Narrative says Illumina should trade.
Illumina Bear Case: Margin Fears Versus Mixed Signals
Bears argue Illumina’s clinical push comes with legal headaches and higher input costs that could eat into profitability and blunt the NovaSeq X payoff.
